Radioligand Therapy Market by Product/Radioligand (Pluvicto, Lutathera, Xofigo), Radionuclide (Lu-177, Ac-225, Ra-223), Radiation Type, Molecular Target (PSMA, SSTR, FAP), Indication, Treatment Line, Route of Administration, End User, and Geography - Global Forecast to 2036

Radioligand Therapy Market Size

The global Radioligand Therapy Market was valued at USD 8.3 billion in 2025 and is projected to reach USD 9.8 billion in 2026. The market is expected to reach USD 45.6 billion by 2036, registering a CAGR of 16.8% during the forecast period (2026–2036).

Key Highlights

• The global Radioligand Therapy Market is projected to reach USD 45.6 billion by 2036, driven by the increasing prevalence of cancer, growing clinical adoption of PSMA-targeted therapies, and expanding radioligand therapy indications beyond prostate cancer and neuroendocrine tumors.
• North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
• By product, Lutetium-177 Vipivotide Tetraxetan (Pluvicto) is expected to account for the largest market share, whereas Actinium-225-based alpha-emitter therapies are projected to witness the fastest growth through 2036.
• By molecular target, PSMA-targeted radioligands are expected to dominate the market, supported by the commercial success of Pluvicto and a deep pipeline of next-generation PSMA-targeted assets.
• Novartis's Pluvicto and Lutathera together generated more than USD 2.2 billion in combined net sales in 2024, underscoring rapid commercial uptake of approved radioligand therapies.
• The FDA approved Pluvicto for earlier-line use in pre-taxane metastatic castration-resistant prostate cancer patients in March 2025, expanding the eligible patient population significantly.
• Persistent global shortages of Lutetium-177 and Actinium-225 supply, coupled with complex cold-chain logistics for short half-life radionuclides, remain key constraints on market scale-up.

Market Overview

The Radioligand Therapy Market comprises targeted radiopharmaceutical products that combine a molecular targeting ligand, such as a peptide, small molecule, or antibody fragment, with a therapeutic radionuclide to selectively deliver cytotoxic radiation to cancer cells while sparing surrounding healthy tissue. These theranostic agents are typically paired with a diagnostic radiotracer counterpart, enabling PET or SPECT-based patient selection, dosimetry planning, and treatment response monitoring, and are used primarily in oncology indications including prostate cancer and neuroendocrine tumors, with an expanding pipeline addressing additional solid tumor types.

The market has been fundamentally reshaped by the commercial success and expanding indications of PSMA-targeted and SSTR-targeted radioligand therapies. Novartis reported that Pluvicto sales increased 42% in 2025, making it one of the company's fastest-growing priority brands. In March 2025, the FDA expanded Pluvicto's indication to PSMA-positive metastatic castration-resistant prostate cancer patients previously treated with an androgen receptor pathway inhibitor who could delay taxane chemotherapy; Novartis reported that the decision approximately tripled the eligible patient population. The market expanded further in July 2026, when the FDA approved Pluvicto in combination with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, extending RLT treatment into an earlier stage of metastatic prostate cancer. Novartis estimates that this latest approval nearly doubles the eligible patient population again. This progression from later-line treatment toward earlier disease settings is substantially increasing the potential addressable population for radioligand therapy and encouraging pharmaceutical companies to invest in additional PSMA-, SSTR-, and other tumor-targeted RLT programs.

Pharmaceutical investment in radioligand therapy is also accelerating, particularly around alpha-emitting radionuclides such as actinium-225. Bristol Myers Squibb completed its approximately US$4.1 billion acquisition of RayzeBio in 2024 to obtain an actinium-based RLT platform and RYZ101, while in July 2025 its RayzeBio subsidiary opened a 77,000-square-foot radiopharmaceutical manufacturing hub in Indianapolis designed for integrated RLT manufacturing and distribution. The facility is designed to enable delivery of RLT products to treatment centers within approximately three days after release, illustrating the increasing importance of geographically distributed manufacturing infrastructure for short-lived therapeutic radionuclides.

Radionuclide supply and manufacturing capacity remain important structural constraints. Novartis reported in July 2026 that five U.S. RLT manufacturing sites were operational or under construction to support the expanding Pluvicto patient population. The short half-lives and specialized production requirements of therapeutic radionuclides such as lutetium-177 and actinium-225 require tightly coordinated production, radiolabeling, quality control, transportation, and administration networks. The combination of rapidly expanding eligible patient populations, 42% Pluvicto sales growth in 2025, new FDA approvals, and investments in dedicated manufacturing facilities is therefore accelerating demand across the entire RLT value chain, from radionuclide production and radiopharmaceutical manufacturing to specialized logistics and nuclear medicine treatment infrastructure.

Market Drivers

Increasing Prevalence of Cancer

The rising global burden of prostate cancer, neuroendocrine tumors, and other solid tumors is expanding the addressable patient population for radioligand therapies, particularly as these treatments demonstrate survival benefits in later-line and increasingly earlier-line treatment settings. According to the WHO's 2026 Global Cancer Observatory update, approximately 20.6 million new cancer cases and 9.8 million cancer deaths occurred globally in 2024, with prostate cancer accounting for approximately 1.5 million new cases, making it the fourth most commonly diagnosed cancer worldwide. WHO also identifies prostate cancer among the five most commonly diagnosed cancers globally, while IARC projects that the global number of prostate cancer cases could reach nearly 3 million annually by 2040, more than doubling from current levels. The expanding cancer burden, aging populations, increasing diagnosis of biomarker-defined tumors, and movement of radioligand therapies into earlier treatment settings are expected to significantly increase the addressable population for targeted radiopharmaceuticals.

Increasing Adoption of Precision Oncology

The broader shift toward biomarker-driven precision oncology is supporting radioligand therapy adoption, as these treatments inherently rely on molecular target expression and PET-based patient selection to identify patients most likely to benefit. The FDA reported 32 notable precision-oncology therapeutic approvals in 2024, highlighting the continued expansion of biomarker-driven cancer treatment. By early 2025, more than 78 FDA-approved drug–companion diagnostic combinations had been identified, while a 2026 analysis of FDA oncology approvals found that companion-diagnostic-associated indications represented 43% of oncology indications by 2022. The FDA's current list also includes imaging tools as companion diagnostics, reinforcing the growing role of molecular and imaging-based patient selection in precision oncology. This expanding use of biomarkers and companion diagnostics is creating a favorable environment for radioligand therapies, which require confirmation of target expression through molecular imaging before treatment.

Market Restraints

Limited Availability of Therapeutic Radionuclides

Global production capacity for key therapeutic radionuclides such as Lutetium-177 and Actinium-225 remains limited relative to anticipated demand growth, creating supply constraints that can limit patient access and slow commercial scale-up of approved therapies.

Complex Manufacturing and Supply Chain Requirements

Radioligand therapy manufacturing requires specialized radiolabeling facilities, stringent quality control processes, and tightly coordinated cold-chain logistics due to the short half-lives of many therapeutic radionuclides, creating significant operational complexity and cost.

Market Opportunities

Expansion into Earlier Lines of Cancer Treatment

Clinical trials evaluating radioligand therapies in earlier treatment lines, exemplified by Pluvicto's 2025 label expansion into pre-taxane mCRPC, are creating substantial opportunities to expand the eligible patient population well beyond current later-line indications.

Development of Alpha-Particle Radioligand Therapies

Growing clinical and commercial interest in alpha-particle emitting radionuclides such as Actinium-225 and Lead-212, which offer higher relative biological effectiveness than beta emitters, is driving substantial investment in next-generation alpha-emitter radioligand therapy development.

Emergence of New Molecular Targets

Continued research into molecular targets beyond PSMA and SSTR, including FAP, GRPR, integrins, and HER2, is expanding the potential application scope of radioligand therapy into additional solid tumor indications.

Market Trends

Rising Momentum Toward Alpha-Emitter Radioligand Therapies

The radioligand therapy field is experiencing a pronounced strategic shift toward alpha-particle emitting radionuclides, reflected in major acquisitions such as Bristol Myers Squibb's purchase of RayzeBio and AstraZeneca's acquisition of Fusion Pharmaceuticals, both aimed at building next-generation alpha-emitter pipelines.

Expanding Theranostic Pairing and Companion Diagnostics

Radioligand therapy developers are increasingly designing therapeutic and diagnostic radiotracer pairs in tandem, reinforcing the theranostic model as the standard development approach and driving parallel growth in companion diagnostic PET imaging adoption.

Segment Analysis

Market Analysis by Product/Radioligand

Based on product and radioligand, the global Radioligand Therapy Market is segmented into Lutetium-177 Vipivotide Tetraxetan (Pluvicto), Lutetium-177 Dotatate (Lutathera), Lutetium-177 PNT2002, Radium-223 Dichloride (Xofigo), Actinium-225 PSMA-617, FPI-2265, TLX591, 225Ac-DOTATATE/225Ac-DOTATOC, 212Pb-DOTAMTATE, 67Cu-SAR-bisPSMA, I-131-1095, and Other Radioligand Therapies.

In 2026, Pluvicto is expected to account for the largest market share, reflecting its established commercial position in metastatic castration-resistant prostate cancer and its recently expanded label into pre-taxane patient populations. However, Actinium-225-based candidates such as Actinium-225 PSMA-617 are projected to register the fastest growth during the forecast period, driven by strong early clinical data and substantial pharmaceutical industry investment in alpha-emitter development.

Market Analysis by Radionuclide

Based on radionuclide, the market is segmented into Lutetium-177, Actinium-225, Radium-223, Lead-212, Copper-67, Iodine-131, Yttrium-90, and Other Radionuclides.

In 2026, Lutetium-177 is expected to account for the largest market share, supported by its use in both Pluvicto and Lutathera, the two leading commercially approved radioligand therapies. However, Actinium-225 is projected to register the fastest growth, driven by expanding clinical development of alpha-emitter therapies across multiple molecular targets.

Market Analysis by Molecular Target

Based on molecular target, the market is segmented into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptors (SSTR), Fibroblast Activation Protein (FAP), Gastrin-Releasing Peptide Receptor (GRPR), Integrins, HER2, Carbonic Anhydrase IX (CAIX), and Other Molecular Targets.

In 2026, PSMA is expected to account for the largest market share, driven by the commercial success of PSMA-targeted therapies in prostate cancer and the depth of the PSMA-targeted clinical pipeline. However, FAP is projected to register the fastest growth, reflecting growing clinical interest in fibroblast activation protein as a target expressed across multiple solid tumor types.

Market Analysis by Indication

Based on indication, the market is segmented into Prostate Cancer, Neuroendocrine Tumors, Other Solid Tumors, Hematological Malignancies, Bone Metastases, and Other Indications.

In 2026, Prostate Cancer is expected to account for the largest market share, led by metastatic castration-resistant prostate cancer, reflecting Pluvicto's established commercial position and expanding label. However, Other Solid Tumors are projected to register the fastest growth, driven by expanding clinical development of radioligand therapies beyond prostate cancer and neuroendocrine tumors.

Market Analysis by End User

Based on end user, the market is segmented into Tertiary Care Academic & Comprehensive Cancer Centers, Specialized Nuclear Medicine Centers, Hospitals, Oncology Clinics, Research & Academic Institutions, and Other End Users.

In 2026, Tertiary Care Academic & Comprehensive Cancer Centers are expected to account for the largest market share, reflecting their established nuclear medicine infrastructure and radiation safety capabilities required for radioligand therapy administration. However, Specialized Nuclear Medicine Centers are projected to register the fastest growth, driven by increasing investment in dedicated radioligand therapy treatment infrastructure.

Geographic Analysis

Based on geography, the global Radioligand Therapy Market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

In 2026, North America is expected to account for the largest share of the global Radioligand Therapy Market. The region's leadership is underpinned by leading RLT developers, established nuclear medicine infrastructure, expanding radiopharmaceutical manufacturing capacity, and a favorable regulatory environment. In July 2026, the FDA approved Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population and expanding RLT use into an earlier stage of metastatic disease. Novartis also had five U.S. RLT manufacturing sites operational or under construction in 2026, including its 10,000-square-foot Carlsbad facility opened in 2025 and a planned Texas facility expected to become operational in 2028. These investments are strengthening the U.S. radioligand manufacturing and distribution infrastructure and supporting continued regional market leadership.

However, Asia-Pacific is projected to register the highest CAGR during the forecast period. The region's growth is being supported by expanding RLT regulatory pathways, increasing radiopharmaceutical manufacturing capacity, and growing adoption of molecular imaging and precision oncology. Japan approved Pluvicto in 2025, and in March 2026 its Pharmaceuticals and Medical Devices Agency (PMDA) issued new considerations for the clinical development of PSMA-targeted PET radiopharmaceuticals, supporting broader adoption of PSMA-based theranostic pathways. Novartis is also expanding its RLT manufacturing footprint in Asia, including planned manufacturing capabilities in Sasayama, Japan, and Haiyan, Zhejiang, China. China's regulatory and treatment infrastructure is also expanding, with the country's Ministry of Ecology and Environment reporting that 21 institutions received radiation-safety licenses in 2025, including cancer and medical institutions. These developments, combined with rising cancer incidence and increasing investment in nuclear medicine infrastructure, are expected to accelerate RLT adoption across Asia-Pacific.

Competitive Landscape

The global Radioligand Therapy Market is moderately consolidated at the commercial stage, with Novartis holding a leading position through Pluvicto and Lutathera, while a broader group of clinical-stage developers, radioisotope producers, and pharmaceutical companies compete across the expanding pipeline. Companies compete primarily on clinical trial data, radionuclide supply security, manufacturing capacity, molecular target differentiation, and strategic partnerships across the radioligand therapy value chain.

Leading market participants are investing heavily in radionuclide production capacity expansion, pursuing strategic acquisitions to build alpha-emitter pipelines, and forming manufacturing and supply partnerships to secure access to constrained therapeutic radionuclides. Major recent moves include Bristol Myers Squibb's acquisition of RayzeBio, AstraZeneca's acquisition of Fusion Pharmaceuticals, and continued capacity investments by Novartis, Curium Pharma, and ITM Isotope Technologies Munich. Capacity expansions, clinical pipeline advancement, and pharmaceutical industry acquisitions remain the key strategies adopted by major vendors in this rapidly growing market.

The report provides a comprehensive competitive assessment of the leading companies operating in the global Radioligand Therapy Market. The key players profiled in the report include Novartis AG, Eli Lilly and Company, POINT Biopharma Global Inc., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, RayzeBio, Inc. (Bristol Myers Squibb), Perspective Therapeutics, Inc., Fusion Pharmaceuticals Inc. (AstraZeneca), Curium Pharma, Eckert & Ziegler SE, Lantheus Holdings, Inc., RadioMedix Inc., Orano Med, and Sofie Biosciences, Inc.

Radioligand Therapy Market Research Summary:

Key Questions Answered in the Report